Mackay Helen J, Wenzel Lari, Mileshkin Linda
From the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre/Deptartment of Medicine, University of Toronto, Ontario, Canada; Department of Medicine and Public Health, University of California, Irvine, Irvine, CA; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
Am Soc Clin Oncol Educ Book. 2015:e299-309. doi: 10.14694/EdBook_AM.2015.35.e299.
Despite the declining incidence of cervical cancer as a result of the introduction of screening programs, globally it remains a leading cause of cancer-related death in women. Outcomes for patients who are diagnosed with anything but early-stage disease remain poor. Here we examine emerging strategies to improve the treatment of locally advanced disease. We discuss emerging biologic data, which are informing our investigation of new therapeutic interventions in persistent, recurrent, and metastatic cervical cancer. We recognize the importance of interventions to improve quality of life and to prevent long-term sequelae in women undergoing treatment. Finally, and perhaps most importantly, we recognize the need for global collaboration and advocacy to improve the outcome for all women at risk of and diagnosed with this disease.
尽管由于引入筛查项目，宫颈癌的发病率有所下降，但在全球范围内，它仍是女性癌症相关死亡的主要原因。被诊断为非早期疾病的患者预后仍然很差。在此，我们探讨改善局部晚期疾病治疗的新策略。我们讨论新出现的生物学数据，这些数据为我们对持续性、复发性和转移性宫颈癌新治疗干预措施的研究提供了依据。我们认识到采取干预措施对于改善接受治疗女性的生活质量以及预防长期后遗症的重要性。最后，或许也是最重要的一点，我们认识到需要全球合作与宣传，以改善所有有患该疾病风险以及被诊断患有该疾病的女性的治疗结果。
